抗IgE治疗抑制重症过敏性哮喘患者循环纤维细胞的趋化、增殖与转化
本研究探讨抗IgE治疗对重症过敏性哮喘(SAA)患者循环纤维细胞活性的影响。奥马珠单抗改善T2-high SAA患者的哮喘控制与肺功能,伴血清IL-33和IL-13下降,并下调纤维细胞CXCR4和CCR7表达、抑制其趋化、增殖及向肌成纤维细胞转化。
要点
- 奥马珠单抗改善T2-high重症过敏性哮喘控制与肺功能。
- 抗IgE下调纤维细胞CXCR4/CCR7,抑制其向肺内募集。
- IL-33/ST2轴参与奥马珠单抗抑制纤维细胞活化的效应。
核心结论
- 奥马珠单抗减少SAA患者循环纤维细胞数量及培养3-7天后纤维细胞和α-SMA+纤维细胞数量。
- IL-33和IL-13可能参与奥马珠单抗抑制纤维细胞活化的有效性,部分解释其减少固有层和基底膜增厚的临床获益。
研究设计与样本
- 研究检测所有哮喘患者循环及培养纤维细胞中CCR7、CXCR4、ST2和α-SMA表达,并在SAA患者奥马珠单抗治疗后重复检测。
- 研究还检测抗IgE治疗对纤维细胞募集、增殖和转化的影响。
主要发现
- 奥马珠单抗有效改善T2-high SAA患者哮喘控制与肺功能,伴血清IL-33和IL-13水平下降。
- 奥马珠单抗下调纤维细胞CXCR4和CCR7表达,可抑制纤维细胞向肺内募集。
- 奥马珠单抗抑制培养3-7天后非贴壁非T(NANT)细胞中增多的纤维细胞和α-SMA+纤维细胞数量。
- 奥马珠单抗降低血清IL-33通过IL-33/ST2轴抑制纤维细胞募集、增殖和肌成纤维细胞转化。
- SAA患者升高的IL-13通过增加ST2表达增强IL-33的效应。
临床怎么用
- 对T2-high重症过敏性哮喘患者,奥马珠单抗除改善哮喘控制与肺功能外,可能通过抑制纤维细胞活化减缓气道重塑。
- 血清IL-33和IL-13水平变化或可作为奥马珠单抗抑制纤维细胞活性的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Circulating fibrocytes act as precursors of myofibroblasts, contribute to airway remodelling in chronic asthma and migrate to injured tissues by expressing CXCR4 and CCR7. Anti-IgE therapy improves severe allergic asthma (SAA) control and airway remodelling in T2-high SAA. The effects of anti-IgE therapy on fibrocyte activities were investigated in this study. METHODS: The expression of CCR7, CXCR4, ST2 and α-SMA (α-smooth muscle actin) in both circulating and cultured fibrocytes from all patients with asthma was measured, and was repeated after omalizumab treatment in SAA. Fibrocytes recruitment, proliferation and transformation were also measured in response to anti-IgE therapy. RESULTS: Omalizumab effectively improved asthma control and pulmonary function in T2-high SAA, associated with a decline in serum levels of IL-33 and IL-13. Omalizumab down-regulates CXCR4 and CCR7 expression of fibrocytes, which could suppress fibrocyte recruitment into the lungs. Omalizumab also suppressed the increased number of fibrocytes and α-SMA+ fibrocytes within the cultured non-adherent non-T (NANT) cells after 3-7 days of culture. The decrease in serum levels of IL-33 by omalizumab contributed to the effectiveness in inhibiting fibrocyte recruitment, proliferation and myofibroblast transformation through IL-33/ST2 axis. The elevated IL-13 expression in SAA patients potentiated the effects of IL-33 by increasing ST2 expression. CONCLUSION: Omalizumab reduced the number of circulating fibrocytes, cell and number of fibrocytes as well as α-SMA+ fibrocytes after 3-7 days of culture in SAA patients. IL-33 and IL-13 may be implicated in the effectiveness of omalizumab in inhibiting fibrocyte activation contributing partly to the clinical benefits in reducing lamina propria and basement membrane thickening.
引用
- Wang CH, Weng CM, Huang TT, et al. Anti-IgE therapy inhibits chemotaxis, proliferation and transformation of circulating fibrocytes in patients with severe allergic asthma. Respirology. 2021. PMID: 34109713. doi:10.1111/resp.14096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。